PLSE 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-06

• In February 2026, we entered into a sales agreement with TD Securities LLC, as sales agent, to issue and sell shares of our common stock for an aggregate offering price of $60 million under an at-the-market (the “February 2026 ATM”) offering program. During the three and six months ended June 30, 20…

• Selling, general and administrative expenses increased by $0.3 million to $8.5 million for the three months ended June 30, 2026, compared to $8.2 million for the three months ended June 30, 2025. The increase was primarily driven by higher expenses of $0.8 million in compensation and other employee-…

• Our condensed consolidated statements of operations as discussed herein are presented below:

• Product revenue was $0.8 million for the six months ended June 30, 2026. There was no revenue for the six months ended June 30, 2025. The total revenue generated was in connection with the limited market release sales of the Vybrance Percutaneous Electrode System, with the first sale occurring in th…

• Cost of product revenue was $0.6 million for the six months ended June 30, 2026. There was no cost of product revenue for the six months ended June 30, 2025.

相对上期删除的文字 · 来源:10-Q · 2026-05-14

• On May 11, 2026, we sold 675,233 shares of common stock in aggregate for net proceeds of approximately $12.9 million, after deducting underwriting discounts, commissions, and offering costs of approximately $0.4 million, pursuant to a sales agreement with TD Securities LLC under an at-the-market off…

• Comparison of the Three Months Ended March 31, 2026 and 2025

• Selling, general and administrative expenses decreased by $1.1 million to $6.6 million for the three months ended March 31, 2026, compared to $7.7 million for the three months ended March 31, 2025. The decrease was primarily driven by a reduction of $2.8 million in stock-based compensation resulting…

• We have funded our business primarily through the issuance of equity securities and debt. To date, we have generated only limited revenue from product sales and we have incurred significant operating losses each year since our inception. Because we intend to continue our investments into new product…

• On May 11, 2026, we sold 675,233 shares of common stock in aggregate for net proceeds of approximately $12.9 million, after deducting discounts, commissions, and offering costs, pursuant to a sales agreement with TD Securities LLC under an at-the-market offering program, to Mr. Robert Duggan, our ma…

相对上期新增的文字 · 来源:10-Q · 2026-08-06

• As further discussed in Note 8 “Segment Reporting” of the Company’s footnotes to our condensed consolidated financial statements, included elsewhere in this Quarterly Report on Form 10-Q, the Company recast prior period significant expenses to conform with current period presentation. Previously fac…

• This information is intended to assist investors in making comparisons of the Company’s historical financial information with future financial information. The reported financial information below has been reclassified to conform to the current presentation.

• The tables below summarizes the reclassified presentation of the Company’s segment reporting:

• 1. Adjusted cost of product revenue includes material costs, cash compensation costs, fees paid to consultants and outside service providers and organizations, and other expenses relating to manufacturing the Company’s commercial products. It does not include stock-based compensation, depreciation, …

• 2. Cross platform research and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, prototype spending and other expenses relating to the acquisition, design and development of the Company’s clinical stage devices.